At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
DFV890 +1 moredrug
Likely dose
DFV890 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating DFV890 and Placebo for Symptomatic Knee Osteoarthritis. Completed, enrolled 115 participants across 31 sites in 8 countries.
Detailed Summary
This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Knee Osteoarthritis
CountriesArgentina, Czechia, Germany, Hungary, Romania, Slovakia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartSep 2021
Primary CompletionDec 2024
Study CompletionDec 2024
TodayJul 2026
First PostedMay 14, 2021
Enrollment StartSep 20, 2021
Primary CompletionDec 14, 2024
Study CompletionDec 23, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.1 years ago
Interventions
DFV890drug
DFV890 was administered orally twice per day, 10 mg during 2 weeks and 25 mg during the next 10 weeks.
Placebodrug
Matching Placebo was administered orally twice per day during 12 weeks.